<DOC>
	<DOCNO>NCT00415181</DOCNO>
	<brief_summary>This study try determine whether certain gene responsible huge variation toxicity effect observe patient treat paclitaxel ( chemotherapeutic drug ) . Specifically study patient ovarian cancer receive paclitaxel/carboplatin chemotherapy primary surgery .</brief_summary>
	<brief_title>Pharmacogenomics Paclitaxel Ovarian Cancer</brief_title>
	<detailed_description>Paclitaxel antineoplastic drug use treatment ovarian cancer . The effect toxicity unpredictable individual patient . Paclitaxel remove ( eliminate ) organism oxidation . CYP2C8 enzyme mainly responsible . P-glycoprotein ( Pgp ) efflux transport protein natural human organism . Pgp responsible excretion drug via bile kidney think play role chemotherapy resistance . Paclitaxel substrate Pgp . Single nucleotide polymorphism possible cause variation CYP2C8 Pgp expression/function . We study possible role genetic variation predictor paclitaxel toxicity effect possible implication individual dosing future . We want determine metabolic capacity approximately 100 ovarian cancer patient compare genotype , acute toxicity ( eg . bone marrow suppression neuropathy ) response treatment ( ie . CA125 response , progression free survival overall survival ) . The metabolic capacity estimate use `` sparse sampling '' approach apply advanced computerized pharmacokinetic/dynamic modelling oppose traditional `` frequent sampling '' pharmacokinetic study burden individual patient . Patients recruited collaboration Oncological department throughout Scandinavia .</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Fallopian Tube Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<criteria>Clinical diagnose histology invasive epithelial ovarian/tuba peritoneal cancer FIGO stage IIbIV grade FIGO IaIIa grade 3 clear cell carcinoma ( stage grade ) Natural candidate paclitaxel 175mg/m2 + Carboplatin ( AUC=56 ) Baseline CA125â‰¥70 AND/OR evaluable disease RECIST ( incl ultrasound ) 18 year old Caucasian ( ie.parents grandparent Caucasian ) Performance status 2 low ( WHO/ECOG ) Prior malignant disease apart cervical carcinoma situ basal cell carcinoma skin Prior chemo / radiotherapy Ongoing imminent chemotherapy Pregnant lactate Fertile woman childbearing potential willing use adequate contraception Neurological symptom ( kind ) bad CTCAE grade 1 Active infection serious disease could impair treatment and/or followup</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2006</verification_date>
	<keyword>CYP2C8</keyword>
	<keyword>MDR1</keyword>
	<keyword>Pharmacogenetics</keyword>
	<keyword>Paclitaxel</keyword>
</DOC>